Back to News
Oct 22, 2025 12:40 PM

Boston Scientific Gains Momentum As Growth Broadens, Goldman Sachs Says

Boston Scientific Corp (NYSE:BSX) delivered "another set of strong top-line results," which trickled down to an earnings beat, according to Goldman Sachs.

BSX stock is showing exceptional strength. Check the market position here.

The Boston Scientific Analyst: Analyst David Roman reiterated a Buy rating and price target of $120.

The Boston Scientific Thesis: The company's total sales grew 20.3% year-on-year to around $5.1 billion, topping the consensus of $5.0 billion, Roman said in the note.

Check out other analyst stock ratings.

Organic revenue grew 15.3%, decelerating from the previous two quarters, but coming in higher than Street expectations of 13.3%, "driven by U.S. Farapulse ...